Related Experiment Video
Updated: Jun 10, 2026
14:58
Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Gamma knife surgery for cavernous hemangiomas in the cavernous sinus
Chiang-Wei Chou1, Hsiu-Mei Wu, Chun-I Huang
1Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital; and School of Medicine, National Yang Ming University, Taipei, Taiwan.
Neurosurgery
|July 22, 2010
Summary
Gamma Knife surgery (GKS) significantly reduces cavernous sinus hemangioma volume, offering an effective alternative to risky microsurgery. This treatment provides long-term benefits for patients with this rare vascular tumor.
Area of Science:
- Neurosurgery
- Vascular Neurology
- Radiation Oncology
Background:
- Cavernous sinus hemangiomas are rare vascular tumors.
- Microsurgery for these tumors carries a high risk of hemorrhage.
- Radiosurgery presents a viable alternative treatment option.
Purpose of the Study:
- To evaluate the efficacy and safety of Gamma Knife surgery (GKS) for treating cavernous sinus hemangiomas.
- To compare GKS outcomes for hemangiomas versus meningiomas in the cavernous sinus.
Main Methods:
- Retrospective analysis of 7 patients with cavernous sinus hemangiomas treated with GKS.
- Comparison with 84 patients with cavernous sinus meningiomas treated during the same period.
- Follow-up via magnetic resonance imaging at 6-month intervals to assess tumor volume and clinical changes.
Main Results:
- GKS achieved significant tumor volume reduction: 72% at 6 months, 80% at 1 year, and up to 90% long-term.
- Cavernous sinus hemangiomas showed greater volume reduction (82% average) compared to meningiomas (29%, P < .001).
- Significant improvement in ophthalmoplegia and vision was observed in most patients post-GKS.
Conclusions:
- Gamma Knife surgery is an effective and safe treatment for cavernous sinus hemangiomas.
- GKS demonstrates superior long-term tumor volume reduction compared to meningiomas.
- GKS is a recommended primary treatment option for cavernous sinus hemangiomas due to microsurgery risks.